T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

BENEDETTA CONTE; Alessandra Fabi; Francesca Poggio; Eva Blondeaux; Chiara Dellepiane; Alessia D'Alonzo; Giuseppe Buono; Grazia Arpino; Valentina Magri; Giuseppe Naso; Daniele Presti; Silvia Mura; Andrea Fontana; Francesco Cognetti; CHIARA MOLINELLI; Simona Pastorino; Claudia Bighin; Loredana Miglietta; Francesco Boccardo; Matteo Lambertini; Lucia Del Mastro

doi:10.1016/j.clbc.2019.09.001

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

BENEDETTA CONTE, Alessandra Fabi, Francesca Poggio, Eva Blondeaux, Chiara Dellepiane, Alessia D'Alonzo, Giuseppe Buono, Grazia Arpino, Valentina Magri, Giuseppe Naso, Daniele Presti, Silvia Mura, Andrea Fontana, Francesco Cognetti, CHIARA MOLINELLI, Simona Pastorino, Claudia Bighin, Loredana Miglietta, Francesco Boccardo, Matteo LambertiniLucia Del Mastro

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.

Lingua originale	Inglese
pagine (da-a)	e181-e187
Numero di pagine	7
Rivista	Clinical Breast Cancer
Volume	20
Numero di pubblicazione	2
DOI	https://doi.org/10.1016/j.clbc.2019.09.001
Stato di pubblicazione	Pubblicato - 2019

Keywords

Advanced breast cancer
Prospective study
Real world evidence
Trastuzumab emtansine

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.clbc.2019.09.001

https://hdl.handle.net/11579/192938

Altri file e collegamenti

handle

Cita questo

CONTE, BENEDETTA., Fabi, A., Poggio, F., Blondeaux, E., Dellepiane, C., D'Alonzo, A., Buono, G., Arpino, G., Magri, V., Naso, G., Presti, D., Mura, S., Fontana, A., Cognetti, F., MOLINELLI, CHIARA., Pastorino, S., Bighin, C., Miglietta, L., Boccardo, F., ... Del Mastro, L. (2019). T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Clinical Breast Cancer, 20(2), e181-e187. https://doi.org/10.1016/j.clbc.2019.09.001

@article{1aef025a961348ada6a728e68d0527ac,

title = "T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study",

abstract = "T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.",

keywords = "Advanced breast cancer, Prospective study, Real world evidence, Trastuzumab emtansine, Advanced breast cancer, Prospective study, Real world evidence, Trastuzumab emtansine",

author = "BENEDETTA CONTE and Alessandra Fabi and Francesca Poggio and Eva Blondeaux and Chiara Dellepiane and Alessia D'Alonzo and Giuseppe Buono and Grazia Arpino and Valentina Magri and Giuseppe Naso and Daniele Presti and Silvia Mura and Andrea Fontana and Francesco Cognetti and CHIARA MOLINELLI and Simona Pastorino and Claudia Bighin and Loredana Miglietta and Francesco Boccardo and Matteo Lambertini and {Del Mastro}, Lucia",

year = "2019",

doi = "10.1016/j.clbc.2019.09.001",

language = "English",

volume = "20",

pages = "e181--e187",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier Inc.",

number = "2",

}

CONTE, BENEDETTA, Fabi, A, Poggio, F, Blondeaux, E, Dellepiane, C, D'Alonzo, A, Buono, G, Arpino, G, Magri, V, Naso, G, Presti, D, Mura, S, Fontana, A, Cognetti, F, MOLINELLI, CHIARA, Pastorino, S, Bighin, C, Miglietta, L, Boccardo, F, Lambertini, M & Del Mastro, L 2019, 'T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study', Clinical Breast Cancer, vol. 20, n. 2, pagg. e181-e187. https://doi.org/10.1016/j.clbc.2019.09.001

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. / CONTE, BENEDETTA; Fabi, Alessandra; Poggio, Francesca et al.
In: Clinical Breast Cancer, Vol. 20, N. 2, 2019, pag. e181-e187.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

AU - CONTE, BENEDETTA

AU - Fabi, Alessandra

AU - Poggio, Francesca

AU - Blondeaux, Eva

AU - Dellepiane, Chiara

AU - D'Alonzo, Alessia

AU - Buono, Giuseppe

AU - Arpino, Grazia

AU - Magri, Valentina

AU - Naso, Giuseppe

AU - Presti, Daniele

AU - Mura, Silvia

AU - Fontana, Andrea

AU - Cognetti, Francesco

AU - MOLINELLI, CHIARA

AU - Pastorino, Simona

AU - Bighin, Claudia

AU - Miglietta, Loredana

AU - Boccardo, Francesco

AU - Lambertini, Matteo

AU - Del Mastro, Lucia

PY - 2019

Y1 - 2019

N2 - T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.

AB - T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.

KW - Advanced breast cancer

KW - Prospective study

KW - Real world evidence

KW - Trastuzumab emtansine

KW - Advanced breast cancer

KW - Prospective study

KW - Real world evidence

KW - Trastuzumab emtansine

UR - https://iris.uniupo.it/handle/11579/192938

U2 - 10.1016/j.clbc.2019.09.001

DO - 10.1016/j.clbc.2019.09.001

M3 - Article

SN - 1526-8209

VL - 20

SP - e181-e187

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 2

ER -

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo